• Tchaikapharma expanded its portfolio with another product

    October 21, 2022

    The newest medicinal product to receive Marketing Authorization from the Medicines Executive Agency is:

    Semefro 50 mg/850 mg film-coated tablets

    Semefro 50 mg/1000 mg film-coated tablets


    Active ingredients: sitagliptin/metformin hydrochloride


    Semefro contains two different medicines called sitagliptin and metformin.

    – Sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors)

    – metformin belongs to a class of medicines called biguanidines.


    They work together to control blood sugar levels in adult patients with a form of diabetes called “type 2 diabetes”. This medication increases the levels of insulin produced after a meal and reduces the amount of sugar produced by the body.


    Along with diet and exercise, the drug helps lower blood sugar.

    The medication can be used alone or with certain other diabetes medications, (insulin, sulfonylurea, or glitazone).


    This is a prescription-only medicinal product.


    ATC code: A10BD07